Holen Sie sich die Stockscreener-App
37.91
0.08%
0.0713
Pharvaris Nv Aktie (PHVS) Neueste Nachrichten
PHVS Maintained by Wells Fargo -- Price Target Raised to $65.00 - GuruFocus
Pharvaris stock gets $60 target at H.C. Wainwright on trial data - Investing.com
Pharvaris’s deucrictibant XR cuts HAE attack rate 83% in Phase III, advancing dual oral strategy - allsci.com
Wells Fargo raises Pharvaris stock price target on strong trial data - Investing.com
RBC Raises Price Target on Pharvaris to $62 From $52, Keeps Outperform, Speculative Risk - marketscreener.com
Citizens raises Pharvaris stock price target to $79 on HAE therapy - Investing.com
Insider at Pharvaris (PHVS) lines up new stock sale - Stock Titan
Oppenheimer raises Pharvaris stock price target on trial results By Investing.com - Investing.com India
Pharvaris N.V. (PHVS) Stock Price | Live Quotes & Charts | NASDAQ - timothysykes.com
Why is Pharvaris stock surging today? By Investing.com - Investing.com Australia
Roivant Sciences, Pharvaris, IonQ And Other Big Stocks Moving Higher On Tuesday - Benzinga
Why is Pharvaris stock surging today? - Investing.com
Why Is Pharvaris Stock Soaring Tuesday? - Benzinga
Premarket Movers for Sept. 8, 2026: Notable Gainers and Losers - ChartMill
Pharvaris Unveils CHAPTER-3 Phase 3 Topline Data and HAE Pipeline Milestones - TipRanks
Morning Market Movers: FCUV, BNC, BIAF, DYN See Big Swings - RTTNews
Rare swelling attacks plunge in Pharvaris (PHVS) pill trial, with key U.S. drug decisions slated for 2027. - Stock Titan
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Pharvaris reports positive phase 3 results for HAE drug By Investing.com - Investing.com Nigeria
Pharvaris posts late-stage trial win for HAE drug (PHVS:NASDAQ) - Seeking Alpha
Pharvaris Posts Strong Phase 3 HAE Prophylaxis Data for Oral Deucrictibant XR - TipRanks
Pharvaris stock surges 27% on positive trial data By Investing.com - Investing.com South Africa
Pharvaris stock surges 27% on positive trial data - Investing.com
Pharvaris reports positive phase 3 results for HAE drug - Investing.com
Pharvaris Announces Positive Topline Data from CHAPTER-3 Pivotal Study of Deucrictibant XR for Prophylaxis of HAE Attacks - Yahoo Finance UK
Moderna Just Doubled Overnight, and 2 More Healthcare Stocks Could Follow It - marketbeat.com
CureVac NV (CVAC) Peer Comparison – Compare with Others - Value Research
Pharvaris (PHVS) Pulls Back 4.5% to $35.32 as Shares Approach Key SupportFibonacci Time Zone - vinanet.vn
Pharvaris (NASDAQ:PHVS) Hits New 12-Month HighWhat's Next? - MarketBeat
Foresite Capital Management V, LLC's Pharvaris NV(PHVS) Holding History - GuruFocus
Pharvaris CEO Berndt Modig Sells 2,292 Shares Under Rule 10b5-1 Trading Plan - Kalkine Media
Insider Selling: Pharvaris (NASDAQ:PHVS) CEO Sells 2,292 Shares - MarketBeat
Pharvaris (PHVS) CEO sells 2,292 shares after RSU vesting - Stock Titan
What is HC Wainwright's Forecast for Pharvaris Q3 Earnings? - MarketBeat
Pharvaris NV (PHVS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Research Analysts Issue Forecasts for Pharvaris Q4 Earnings - MarketBeat
General Atlantic group (PHVS) discloses 5.36M Pharvaris shares, 7.6% ownership - Stock Titan
PHVS (NASDAQ: PHVS) holder Berndt Modig plans 2,292-share stock sale - Stock Titan
H.C. Wainwright reiterates Pharvaris stock rating on regulatory progress By Investing.com - Investing.com Nigeria
H.C. Wainwright reiterates Pharvaris stock rating on regulatory progress - Investing.com
Pharvaris President Lu Peng Reports Two RSU Tax Withholding Share Dispositions - Kalkine Media
PHVS Maintains Outperform Rating -- Price Target Raised to $52.0 - GuruFocus
Pharvaris Could See Significant Upside on Positive Phase 3 Data, RBC Says - marketscreener.com
PHVS Maintains Rating by Citizens -- Price Target Raised to $75. - GuruFocus
RBC Adjusts PT on Pharvaris to $52 From $51, Maintains Outperform Speculative Risk Rating - marketscreener.com
Citizens raises Pharvaris stock price target to $75 on trial progress - Investing.com Australia
Pharvaris (NASDAQ:PHVS) Reaches New 12-Month HighWhat's Next? - MarketBeat
Pharvaris (NASDAQ:PHVS) Sees Unusually-High Trading VolumeHere's What Happened - MarketBeat
Pharvaris Q2 EPS of $(0.81) misses $(0.74) analyst estimate - scanx.trade
Pharvaris N.V. reports results for the quarter ended June 30Earnings Summary - TradingView
(PHVS) as a Liquidity Pulse for Institutional Tactics - news.stocktradersdaily.com
Pharvaris Posts Q2 2026 Results as Deucrictibant Nears Key Phase 3 Data and Regulatory Milestones - TipRanks
Pharvaris' Q2 Loss Per Share Narrows - marketscreener.com
Earnings Flash (PHVS) Pharvaris Posts Q2 Loss 0.70 Euro a Share - marketscreener.com
Pharvaris Reports Q2 2026 Results and Updates on Deucrictibant Development, Regulatory Progress and Financial Position - Quiver Quantitative
Pharvaris (PHVS) boosts cash to €318M as deucrictibant nears key data and FDA date - Stock Titan
Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update - Enidnews.com
Pharvaris N.V. $PHVS Shares Sold by The Manufacturers Life Insurance Company - MarketBeat
Pharvaris N.V. (NASDAQ:PHVS) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Can Pharvaris (PHVS) Turn AAE-C1INH Patient Insights Into a Lasting Clinical Advantage? - Sahm
Claude AI's Latest Portfolio Additions Spotlight Pharvaris and Micron as Hedge Fund FavoritesROIC Trend Report - dars.gov.et
0.28%
3.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):